My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 103

    1.

    New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.

    Cang S, Ma Y, Liu D.

    J Hematol Oncol. 2009 Jun 1;2:22.PMID: 19486511 [PubMed - in process]Related articlesFree article

    2.

    Histone deacetylase inhibitors in cancer therapy.

    Lane AA, Chabner BA.

    J Clin Oncol. 2009 Nov 10;27(32):5459-68. Epub 2009 Oct 13. Review.PMID: 19826124 [PubMed - indexed for MEDLINE]Related articles

    3.

    Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.

    Ganesan A, Nolan L, Crabb SJ, Packham G.

    Curr Cancer Drug Targets. 2009 Dec;9(8):963-81. Review.PMID: 20025605 [PubMed - indexed for MEDLINE]Related articles

    4.

    Epigenetic alterations and cancer: new targets for therapy.

    Allen A.

    IDrugs. 2007 Oct;10(10):709-12. Review.PMID: 17899489 [PubMed - indexed for MEDLINE]Related articles

    5.

    Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.

    Duvic M, Vu J.

    Expert Opin Investig Drugs. 2007 Jul;16(7):1111-20. Review.PMID: 17594194 [PubMed - indexed for MEDLINE]Related articles

    6.

    Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

    Santini V, Gozzini A, Ferrari G.

    Curr Drug Metab. 2007 May;8(4):383-93. Review.PMID: 17504226 [PubMed - indexed for MEDLINE]Related articles

    7.

    Histone Deacetylases and epigenetic therapies of hematological malignancies.

    Mercurio C, Minucci S, Pelicci PG.

    Pharmacol Res. 2010 Feb 25. [Epub ahead of print]PMID: 20219679 [PubMed - as supplied by publisher]Related articles

    8.

    Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.

    Tan J, Cang S, Ma Y, Petrillo RL, Liu D.

    J Hematol Oncol. 2010 Feb 4;3:5.PMID: 20132536 [PubMed - in process]Related articlesFree article

    9.

    Histone deacetylase inhibitors for cancer therapy.

    Kim TY, Bang YJ, Robertson KD.

    Epigenetics. 2006 Jan-Mar;1(1):14-23. Epub 2006 Mar 1. Review.PMID: 17998811 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.

    Dobosy JR, Roberts JL, Fu VX, Jarrard DF.

    J Urol. 2007 Mar;177(3):822-31. Review.PMID: 17296351 [PubMed - indexed for MEDLINE]Related articles

    11.

    Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.

    Schneider-Stock R, Ocker M.

    IDrugs. 2007 Aug;10(8):557-61. Review.PMID: 17665331 [PubMed - indexed for MEDLINE]Related articles

    12.

    Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

    Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M.

    J Cell Physiol. 2007 Aug;212(2):330-44. Review.PMID: 17458893 [PubMed - indexed for MEDLINE]Related articles

    13.

    Epigenetic interplay between histone modifications and DNA methylation in gene silencing.

    Vaissière T, Sawan C, Herceg Z.

    Mutat Res. 2008 Jul-Aug;659(1-2):40-8. Epub 2008 Feb 29. Review.PMID: 18407786 [PubMed - indexed for MEDLINE]Related articles

    14.

    T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.

    Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, Torrico S, Bates SE.

    Blood. 2004 Jun 15;103(12):4636-43. Epub 2004 Mar 2.PMID: 14996704 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Histone deacetylase inhibitors for epigenetic therapy of cancer.

    Monneret C.

    Anticancer Drugs. 2007 Apr;18(4):363-70. Review. Erratum in: Anticancer Drugs. 2007 Jun;18(5):219. PMID: 17351388 [PubMed - indexed for MEDLINE]Related articles

    16.

    Chromatin-remodelling mechanisms in cancer.

    Lafon-Hughes L, Di Tomaso MV, Méndez-Acuña L, Martínez-López W.

    Mutat Res. 2008 Mar-Apr;658(3):191-214. Epub 2008 Feb 17. Review.PMID: 18403253 [PubMed - indexed for MEDLINE]Related articles

    17.

    Histone deacetylase inhibitors as novel anticancer therapeutics.

    Walkinshaw DR, Yang XJ.

    Curr Oncol. 2008 Oct;15(5):237-43.PMID: 19008999 [PubMed]Related articlesFree article

    18.

    Histone deacetylase inhibitors: current status and overview of recent clinical trials.

    Ma X, Ezzeldin HH, Diasio RB.

    Drugs. 2009 Oct 1;69(14):1911-34. doi: 10.2165/11315680-000000000-00000. Review.PMID: 19747008 [PubMed - indexed for MEDLINE]Related articles

    19.

    New anti-cancer strategies: epigenetic therapies and biomarkers.

    Balch C, Montgomery JS, Paik HI, Kim S, Kim S, Huang TH, Nephew KP.

    Front Biosci. 2005 May 1;10:1897-931. Review.PMID: 15769674 [PubMed - indexed for MEDLINE]Related articles

    20.

    Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.

    Khan O, La Thangue NB.

    Nat Clin Pract Oncol. 2008 Dec;5(12):714-26. Epub 2008 Oct 7. Review.PMID: 18839006 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk